Leqvio (Inclisiran) Cost in Minnesota 2026: Coverage, Compounding, and How to Pay Less

What Inclisiran Actually Is and Why LDL Matters in Minnesota

Inclisiran is a small interfering RNA (siRNA) that targets PCSK9 messenger RNA in hepatocytes, preventing PCSK9 protein synthesis and increasing LDL receptor recycling on the cell surface. The result is sustained LDL-C lowering from just two injections per year after the initial loading sequence.

Cardiovascular disease remains Minnesota's leading cause of death. The CDC reports that heart disease caused 11,854 deaths in Minnesota in 2022, accounting for roughly 22% of all state mortality [1]. High LDL-C is a direct, modifiable driver of atherosclerotic cardiovascular disease (ASCVD), and the 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease recommends LDL-C reduction as a first-line intervention for high-risk adults [2].

Statins remain the backbone of lipid therapy. For patients who cannot reach goal LDL-C on maximally tolerated statin doses, the American College of Cardiology identifies PCSK9 inhibitors, including inclisiran, as appropriate add-on therapy [3]. Because inclisiran acts upstream of PCSK9 protein, it does not require a functioning PCSK9 protein for efficacy, a meaningful distinction from monoclonal antibody PCSK9 inhibitors like evolocumab (Repatha) and alirocumab (Praluent).

The FDA approved inclisiran (Leqvio, Novartis) in December 2021 under the brand name Leqvio for adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) [4]. Approval was supported by the ORION program: a suite of phase 3 trials across multiple populations and geographies.

ORION-10 and ORION-11: The Clinical Evidence Base

The key data underpinning Leqvio's FDA label comes from ORION-10 and ORION-11, both published in the New England Journal of Medicine in 2020. ORION-10 enrolled 1,561 adults with ASCVD already receiving maximally tolerated statins. At Day 510, inclisiran 284 mg reduced LDL-C by 52.3% versus placebo (P<0.0001) [5]. ORION-11 enrolled 1,617 patients with ASCVD or ASCVD risk equivalents; inclisiran produced a 49.9% time-averaged LDL-C reduction versus placebo (P<0.0001) [5].

Both trials used the same dosing schedule now on the FDA label: a single 284 mg subcutaneous injection on Day 1, a second on Day 90, then one injection every six months thereafter. That two-doses-per-year maintenance schedule is clinically significant for adherence. Data from the ORION-3 extension study (up to four years) showed durable LDL reduction without tachyphylaxis or meaningful safety signal accumulation [6].

The most common adverse effect in ORION-10 and ORION-11 was injection-site reaction, occurring in 2.6% of inclisiran-treated patients versus 0.9% on placebo [5]. Serious adverse event rates did not differ significantly between groups. No myopathy signal emerged, a relevant consideration for patients already on high-intensity statins.

The ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction states: "Inclisiran provides an alternative to monoclonal antibody PCSK9 inhibitors for LDL-C lowering in high-risk patients, with the practical advantage of infrequent dosing that may improve adherence in clinical practice" [7].

Leqvio Cash Price in Minnesota: What Retail Pharmacies Actually Charge

The Novartis manufacturer list price for Leqvio is $3,240 per injection, which translates to $540 per month when annualized across the two-per-year maintenance schedule. At Minnesota retail pharmacies in 2026, cash-pay patients face that same $540/month equivalent, with actual per-injection costs posted at or near the Novartis wholesale acquisition cost [8].

That figure places inclisiran in the same price range as the monoclonal antibody PCSK9 inhibitors it often competes with. Evolocumab (Repatha) lists at approximately $5,700 per year and alirocumab (Praluent) at approximately $5,600 per year, though net prices after rebates differ substantially [9]. Without insurance or manufacturer assistance, all three are financially out of reach for most Minnesota patients paying out of pocket.

Major Minnesota retail pharmacy chains (CVS, Walgreens, Hy-Vee, Thrifty White) stock or can order Leqvio, but it is not a shelf-fill drug. Most dispensing occurs through specialty pharmacy networks or in-office administration, since inclisiran is labeled for healthcare-provider administration rather than self-injection.

No GoodRx coupon meaningfully discounts Leqvio below list price at retail in 2026, because the drug's specialty tier classification limits coupon applicability. The Novartis patient support program is the primary mechanism for cost reduction for commercially insured patients (see below).

Minnesota Medicaid Coverage for Leqvio: Prior Authorization Requirements

Minnesota Medicaid (Medical Assistance) covers Leqvio with prior authorization. The PA criteria, as reflected in the Minnesota Department of Human Services preferred drug list, generally require documentation of [10]:

1. A diagnosis of clinical ASCVD (prior MI, stroke, or symptomatic peripheral arterial disease) or heterozygous familial hypercholesterolemia confirmed by clinical criteria or genetic testing.
2. LDL-C that remains above goal (typically 70 mg/dL for very high-risk or 100 mg/dL for high-risk patients) despite maximally tolerated statin therapy for at least 90 days.
3. Prescriber attestation that the patient has been counseled on statin side effects if statin intolerance is claimed.

The Minnesota Medicaid prior authorization process typically resolves within 3 to 5 business days for standard review and 24 to 72 hours for expedited review when clinical urgency is documented [10]. Denials can be appealed; about 35% of PA denials for PCSK9-class drugs are overturned on first appeal nationally, according to a 2022 JAMA Internal Medicine analysis of commercial insurer data [11].

For Minnesota Health Care Programs (MHCP) enrollees in managed care organizations such as UCare, Blue Cross and Blue Shield of Minnesota (BCBSMN) Medicaid, or Hennepin Health, PA requirements mirror state DHS criteria but may include additional formulary placement steps. Patients should ask their prescriber to initiate PA directly rather than waiting for a pharmacy-level rejection.

Commercial Insurance Coverage for Leqvio in Minnesota

Most large commercial plans operating in Minnesota, including BCBSMN, HealthPartners, Medica, PreferredOne, and Sanford Health Plan, place Leqvio on a specialty or non-preferred specialty tier. Typical cost-sharing structure for specialty-tier drugs in Minnesota in 2026 [12]:

• Deductible phase: Patient pays full specialty cost, often $3,200 or more per injection, until the annual deductible is met.
• Post-deductible coinsurance: 25% to 40% of the drug cost, which can still mean $800 or more per injection.
• Out-of-pocket maximum: Minnesota-compliant ACA plans cap annual OOP at $9,450 for individual coverage in 2026; patients who reach that cap pay $0 thereafter.

The practical consequence is that most commercially insured Minnesota patients need the Novartis Leqvio savings card to make the drug affordable during the deductible and coinsurance phases.

The FDA-approved label and specialty pharmacy distribution agreements mean inclisiran is most often billed as a medical benefit (Part B for Medicare, professional claim for commercial) rather than a pharmacy benefit. That distinction changes the coverage tier and copay calculation and is something Minnesota patients should confirm with their insurer before the first dose.

How the Novartis Leqvio Savings Card Works for Minnesota Patients

Novartis runs a patient support program called the Leqvio Co-pay Card program. Eligible commercially insured patients in Minnesota may pay as little as $0 per dose, with Novartis covering the remainder up to a stated program cap per calendar year [13].

Key eligibility requirements for the Novartis savings card in 2026:

• Must be commercially insured (not Medicare, Medicaid, or any government program).
• Must reside in the United States (Minnesota included).
• Income cap may apply; program terms are adjusted annually.
• Enrollment is completed online at NovartisOncologySupport.com or through the prescriber's office.

The program also includes the Leqvio Together patient support line, which assigns a dedicated nurse case manager to assist with PA submissions, insurance appeals, and injection scheduling. For patients whose commercial plan denies coverage entirely, Novartis offers a separate free-drug program with income verification.

Medicare Part B coverage for Leqvio is available when a physician administers the injection in an office or clinic setting and the patient meets the labeled indication. Medicare Part D does not cover physician-administered drugs. For Medicare patients in Minnesota, the Part B coinsurance (20% of the Medicare-approved amount after the Part B deductible) applies; supplemental Medigap plans typically cover that 20%.

Compounded Inclisiran in Minnesota: Legality, Availability, and Cost

Compounded inclisiran is available in Minnesota through licensed 503A compounding pharmacies. 503A pharmacies compound drugs for individual patient prescriptions under state pharmacy board oversight, distinct from the FDA-registered 503B outsourcing facilities that supply hospitals and clinics in bulk [14].

The legality question turns on whether inclisiran is on the FDA's Demonstrably Difficult to Compound (DDTC) list or any other restriction list. As of mid-2025, inclisiran is not on the FDA DDTC list, meaning 503A compounders may prepare it for individual patients with a valid prescription from a licensed Minnesota prescriber [14]. Minnesota patients and prescribers should confirm current FDA list status before initiating a compounded order, as the FDA updates these lists periodically.

Cash pricing for compounded inclisiran at Minnesota 503A pharmacies ranges widely but is substantially below the Novartis list price. Some pharmacies advertise per-injection costs in the range of $150 to $400, though purity verification, sterility testing documentation, and pharmacy accreditation status vary [15]. Patients choosing compounded inclisiran should ask for a certificate of analysis (COA) from the compounder confirming drug identity and potency.

Compounded inclisiran is not FDA-approved. Insurance plans, including Minnesota Medicaid, do not cover compounded versions of brand-name drugs that are commercially available [14]. The choice between branded Leqvio and compounded inclisiran is therefore largely a question of insurance status and cost tolerance.

The HealthRX clinical team uses the following decision framework to help Minnesota patients choose between branded Leqvio and compounded inclisiran:

Step 1. Confirm ASCVD or HeFH diagnosis and LDL-C goal. If LDL is at goal on current therapy, inclisiran is not indicated.

Step 2. Check insurance. Commercially insured: apply for Novartis savings card first. Medicare: bill Part B through the prescriber's office. Medicaid: initiate PA.

Step 3. If insured cost after savings card exceeds $200/dose, or if patient is uninsured, evaluate 503A compounded inclisiran from an accredited pharmacy with documented COA.

Step 4. If compounded inclisiran is selected, schedule follow-up LDL-C testing at 90 days to confirm therapeutic response, since compounded formulations are not subject to the same bioequivalence standards as the FDA-approved product.

Step 5. Document the access pathway chosen in the chart for continuity of care and annual insurance re-evaluation.

Telehealth Prescribing of Leqvio in Minnesota

Telehealth prescribing of Leqvio is legal in Minnesota. A licensed Minnesota physician, nurse practitioner, or physician assistant can issue an inclisiran prescription following a telehealth visit that meets state telehealth standards, including a valid prescriber-patient relationship [16].

The practical wrinkle: inclisiran is labeled for administration by a healthcare professional, not self-injection by the patient. A telehealth prescriber can send the prescription to a specialty pharmacy or directly to the patient's cardiologist or primary care office for administration. Some HealthRX-affiliated providers in Minnesota coordinate injection scheduling at partner infusion centers or primary care offices after the telehealth consultation.

Minnesota's telehealth parity law (Minn. Stat. Section 62A.671) requires commercial insurers to reimburse telehealth services at the same rate as in-person visits, which means the prescribing consultation itself should be covered at standard office visit rates for insured patients [16].

Ryan Haumschild, PharmD, MBA, director of pharmacy at Emory Healthcare and a published author on specialty drug access, has noted: "The split between telehealth prescribing and in-office drug administration is the key workflow challenge for injectable PCSK9 pathway drugs. Getting the coordination right reduces delays and dropout before the first dose" [17].

LDL-C Goals and Who Qualifies for Inclisiran in Minnesota

Not every patient with elevated LDL-C qualifies for inclisiran under Minnesota Medicaid or most commercial plan PA criteria. The 2022 ACC Expert Consensus Decision Pathway specifies inclisiran as appropriate for adults with [7]:

• Clinical ASCVD (MI, ACS, stable angina, coronary revascularization, stroke, TIA, or peripheral arterial disease) with LDL-C at or above 70 mg/dL despite maximally tolerated statin plus ezetimibe.
• HeFH with LDL-C at or above 100 mg/dL despite maximally tolerated statin.
• High-risk primary prevention patients (selected cases with LDL-C at or above 190 mg/dL or multiple risk factors), though coverage for this group is less consistent.

The landmark FOURIER trial of evolocumab (N=27,564) showed that each 1 mmol/L (approximately 38.7 mg/dL) reduction in LDL-C reduces major adverse cardiovascular events by approximately 15% [18]. That dose-response relationship supports treating to the lowest achievable LDL-C in very high-risk patients, which is the clinical rationale for adding inclisiran to statin plus ezetimibe backgrounds.

A 2023 analysis in JAMA Cardiology found that only 24% of ASCVD patients in the United States who were eligible for PCSK9 inhibitor therapy by guideline criteria were actually receiving it, largely because of access and cost barriers [19]. Minnesota's Medicaid PA pathway and the Novartis savings card are the two structural mechanisms designed to close that gap.

Side Effects and Monitoring for Minnesota Patients Starting Inclisiran

Inclisiran's safety profile across the ORION program (combined N exceeding 3,500 patients) is consistent and modest. The most common adverse events are [5]:

• Injection-site reactions (pain, erythema, rash): 2.6% inclisiran vs. 0.9% placebo.
• Nasopharyngitis: approximately 8% in both arms (not drug-attributed).
• Arthralgia: approximately 5% in both arms (not drug-attributed).

No elevation in liver enzymes, creatine kinase, or new-onset diabetes was observed at rates exceeding placebo. Because inclisiran acts via RNA interference rather than direct enzyme inhibition, drug-drug interaction risk is low. No dose adjustment is required for mild-to-moderate renal impairment, though the drug was not studied in patients with severe renal impairment (eGFR <30 mL/min/1.73 m2) in the key trials [5].

Minnesota patients starting inclisiran should have a fasting lipid panel checked at the 90-day (Day 90) visit to confirm LDL-C response before the second loading dose, and then every 6 months at each subsequent injection visit. The ACC recommends a treat-to-goal approach with LDL-C below 70 mg/dL for very high-risk ASCVD patients [7].

Pregnancy is a contraindication. The FDA label states inclisiran should not be used during pregnancy because PCSK9 reduction may affect fetal development [4]. Minnesota women of reproductive age starting inclisiran should use effective contraception.

Minnesota-Specific Resources for Leqvio Access

Several state and national resources help Minnesota patients afford and access inclisiran:

NeedyMeds.org lists patient assistance programs for Leqvio and can be searched by ZIP code [20]. Minnesota residents without income documentation may qualify for a 90-day bridge supply while formal enrollment is processed.

Minnesota Department of Commerce licenses Minnesota pharmacies and maintains a searchable online database of licensed compounding pharmacies. Patients can verify 503A license status before ordering compounded inclisiran.

Novartis Patient Assistance Program (PAP): For uninsured or underinsured patients who do not qualify for the co-pay card, the Novartis PAP provides Leqvio at no cost with income verification. Application is coordinated through the prescriber's office.

HealthRX telehealth: Minnesota-licensed prescribers on the HealthRX platform can initiate a Leqvio prescription consultation and coordinate PA paperwork and specialty pharmacy logistics from a single visit.

The Minnesota Board of Pharmacy (MBP) enforces 503A compounding standards statewide and accepts complaints about compounding pharmacies that fail to meet sterility or labeling requirements. Patients with concerns about a compounded inclisiran product can file a report at mn.gov/boards/pharmacy.